ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer

Urology

Volumn 75, Issue 4, 2010, Pages 762-767

  Perner, Sven ^a   Svensson, Maria A ^a,b   Hossain, Ruhella R ^a   Day, John R ^c   Groskopf, Jack ^c   Slaughter, Ryan C ^c   Jarleborn, Analee R ^c   Hofer, Matthias D ^d   Kuefer, Rainer ^e   Demichelis, Francesca ^a   Rickman, David S ^a   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c Gen Probe Incorporated   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLONAL VARIATION; DISEASE PREDISPOSITION; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TMPRSS2 GENE; TUMOR VOLUME;

AGED; GENE REARRANGEMENT; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS;

EID: 77950300309     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.10.010     Document Type: Article

References (31)

1. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
2. Perner S., Mosquera J.M., Demichelis F., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31 (2007) 882-888
3. Mehra R., Tomlins S.A., Shen R., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007) 538-544
4. Hermans K.G., van Marion R., van Dekken H., et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66 (2006) 10658-10663
5. Tomlins S.A., Mehra R., Rhodes D.R., et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66 (2006) 3396-3400
6. Han B., Mehra R., Dhanasekaran S.M., et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68 (2008) 7629-7637
7. Demichelis F., Fall K., Perner S., et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599
8. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 (2008) 253-263
9. Gopalan A., Leversha M.A., Satagopan J.M., et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 (2009) 1400-1406
10. Mehra R., Tomlins S.A., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
11. Greene D.R., Wheeler T.M., Egawa S., et al. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146 (1991) 1069-1076
12. Ruijter E.T., van de Kaa C.A., Schalken J.A., et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180 (1996) 295-299
13. Arora R., Koch M.O., Eble J.N., et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100 (2004) 2362-2366
14. Mehra R., Han B., Tomlins S.A., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67 (2007) 7991-7995
15. Clark J., Attard G., Jhavar S., et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27 (2008) 1993-2003
16. Barry M., Perner S., Demichelis F., et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70 (2007) 630-633
17. Hofer M.D., Kuefer R., Huang W., et al. Prognostic factors in lymph node-positive prostate cancer. Urology 67 (2006) 1016-1021
18. Cheng L., Song S.Y., Pretlow T.G., et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90 (1998) 233-237
19. Perner S., Demichelis F., Beroukhim R., et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 (2006) 8337-8341
20. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
21. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
22. Wang J., Cai Y., Ren C., et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66 (2006) 8347-8351
23. Pflueger D., Rickman D.S., Sboner A., et al. Transcriptome sequencing identifies NDRG1-ERG fusion prostate cancer. Neoplasia 11 (2009) 804-811
24. Paris P.L., Hofer M.D., Albo G., et al. Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer. Neoplasia 8 (2006) 1083-1089
25. Klezovitch O., Risk M., Coleman I., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105 (2008) 2105-2110
26. Tomlins S.A., Laxman B., Varambally S., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2008) 177-188
27. Carver B.S., Tran J., Gopalan A., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41 (2009) 619-624
28. King J.C., Xu J., Wongvipat J., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41 (2009) 524-526
29. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (2009) 2912-2918
30. Rubin M.A., Gerstein A., Reid K., et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 31 (2000) 504-508
31. Laxman B., Morris D.S., Yu J., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68 (2008) 645-649